ICD-10 Coding for Uterine Cancer(C54.1, C54.1B, C54.1M)
Comprehensive guide to ICD-10 coding for uterine cancer, including endometrial and myometrial cancer. Learn about code relationships, documentation requirements, and common pitfalls.
Complete code families applicable to Uterine Cancer
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C54.1 | Malignant neoplasm of endometrium | Use when biopsy confirms endometrial adenocarcinoma. |
|
| C54.2 | Malignant neoplasm of myometrium | Use when biopsy confirms myometrial sarcoma. |
|
| C55 | Malignant neoplasm of uterus, part unspecified | Use when the specific site within the uterus cannot be determined. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutUterine Cancer
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Uterine Cancer.
Coding atypical endometrial hyperplasia as D07.0.
Impact
Clinical: Misrepresentation of patient condition., Regulatory: Non-compliance with coding standards., Financial: Potential for claim denial.
Mitigation
Verify histology before coding, Use N85.02 for hyperplasia without atypia
Using C55 for endometrial cancer with incomplete staging.
Impact
Reimbursement: May lead to reduced reimbursement due to lack of specificity., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate data representation in patient records.
Mitigation
Code C54.1 if biopsy confirms endometrial origin, even if staging is pending.
Histology documentation
Impact
Lack of specific histology documentation can lead to coding errors.
Mitigation
Ensure biopsy results are documented and reviewed before coding.